![Yang Lu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 222 M $ al 31/07/2026
Yang Lu is the founder of Adlai Nortye Ltd., where he currently serves as the Chairman & Chief Executive Officer.
He founded the company in 2018.
Mr. Lu previously worked as the Managing Director at Sinopep-Allsino Bio Pharmaceutical Co., Ltd. from 2004 to 2006.
Mr. Lu holds an MBA from China Europe International Business School, which he obtained in 2012.
He also completed his undergraduate studies at Xiamen University in 2002.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 10/04/2026 | 16.990.000 ( 100 % ) | 221 M $ | 31/07/2026 | |
ADLAI NORTYE GROUP LTD. 0,32 % | 13/05/2026 | 299.970 ( 0,32 % ) | 1 M $ | 31/07/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| ADLAI NORTYE LTD. | Director Ejecutivo | 09/05/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
| JIANGSU SINOPEP-ALLSINO BIOPHARMACEUTICAL CO., LTD. | Director Ejecutivo | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 4 |
|---|---|
China Europe International Business School
 China Europe International Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Xiamen University
 Xiamen University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sinopep-Allsino Bio Pharmaceutical Co., Ltd.
 Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in research, development, production and sale of peptide and small molecule chemical drugs | Health Technology |
Adlai Nortye Ltd.
 Adlai Nortye Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and development of biopharmaceuticals for cancer immunotherapy | Commercial Services |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
